secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001193125-23-300042
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin settles with Elliott; appoints 3 new directors, forms strategic review committee
--------------------------------------------------------------------------------

- Board expanded to 15 directors; appoints Barbara Bodem, Athena Countouriotis, Mark Enyedy as independent directors effective Dec 27, 2023.
- New Strategic and Operating Review Committee chaired by Richard Meier; includes CEO Alexander Hardy and Maykin Ho; to review business, strategy, and capital allocation.
- Cooperation agreement with Elliott includes standstill, voting commitments, and mutual non-disparagement; Elliott supports the changes.
- Company commits to holding an investor day in 2024 after committee recommendations; Elliott entered into information-sharing agreement for JPM conference and earnings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/0001193125-23-300042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523300042/d488420d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-300042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer